P. Rosenstiel

发表

clinical and MRI outcomes in multiple sclerosis

Jeffrey A. Cohen, F. Barkhof, L. Kappos, 2015 .

Fingolimod First-Dose Effects In Patients With Relapsing-Remitting Multiple Sclerosis Concomitantly Treated With Serotonin-Specific Reuptake Inhibitors (P7.233)

R. Bermel, D. Kantor, Xiangyi Meng, 2014 .

Fingolimod-Effect on Brain Atrophy and Clinical/MRI Correlations in Three Phase 3 Studies – TRANSFORMS, FREEDOMS and FREEDOMS II (S51.006)

Jeffrey A. Cohen, F. Barkhof, L. Kappos, 2013 .

Exacerbation of Apoptosis in the Dentate Gyrus of the Aged Rat by Dexamethasone and the Protective Role of Corticosterone

F. Holsboer, O. Almeida, A. H. Hassan, 1996, Experimental Neurology.

Brivaracetam in Unverricht‐Lundborg disease (EPM1): Results from two randomized, double‐blind, placebo‐controlled studies

F. Andermann, P. Genton, E. Andermann, 2016, Epilepsia.

Brivaracetam (UCB 34714)

P. Rosenstiel, 2011, Neurotherapeutics.

Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19

Konrad U. Förstner, Philipp H. Schiffer, Joseph M. Johnson, 2021, Immunity.

The prototypic mineralocorticoid receptor agonist aldosterone influences neurogenesis in the dentate gyrus of the adrenalectomized rat

B. Czéh, E. Fuchs, D. Goula, 2002, Brain Research.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Ludwig Kappos, Ernst-Wilhelm Radue, Peter A Calabresi, 2014, The Lancet Neurology.

Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.004)

S. Haeberlein, R. Nitsch, C. Hock, 2018 .

Baseline Characteristics From ENGAGE and EMERGE: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease (P4.1-001)

S. Haeberlein, S. Salloway, P. Aisen, 2019 .

Induction of Periimplantitis in Dental Implants

H. Bolte, B. Beck-Broichsitter, O. Gavrilova, 2013, The Journal of craniofacial surgery.

Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO)

X. Montalban, L. Kappos, N. Mueller-Lenke, 2013 .

Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102)

D. Goodin, L. Kappos, P. Calabresi, 2013 .

Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis

X. Montalban, L. Kappos, G. Comi, 2015, Journal of Neurology.

Relapses in patients treated with fingolimod after previous exposure to natalizumab

L. Kappos, G. Comi, R. Gold, 2015, Multiple sclerosis.

Fingolimod reduces the number of severe relapses in patients with relapsing multiple sclerosis: Results from phase III TRANSFORMS and FREEDOMS studies

L. Kappos, H. Hartung, G. Francis, 2011 .

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.

S. Haeberlein, P. Chiao, A. Sandrock, 2017, The journal of prevention of Alzheimer's disease.

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.

R. Bermel, D. Kantor, R. Hashmonay, 2015, Multiple sclerosis and related disorders.

Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis

X. Montalban, L. Kappos, E. Radue, 2014, Multiple sclerosis.

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).

F. Barkhof, L. Kappos, H. Hartung, 2014, Multiple sclerosis and related disorders.

Adjunctive brivaracetam for refractory partial-onset seizures

J. French, J. French, P. von Rosenstiel, 2010, Neurology.

Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis (P07.116)

D. MacManus, X. Montalban, L. Kappos, 2013, Neurology.